W
Wenqiu Wang
Researcher at University of California, San Diego
Publications - 16
Citations - 1933
Wenqiu Wang is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Protein aggregation & DNA methylation. The author has an hindex of 11, co-authored 15 publications receiving 1287 citations. Previous affiliations of Wenqiu Wang include Shanghai Jiao Tong University.
Papers
More filters
Journal ArticleDOI
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Rui-Hua Xu,Wei Wei,Wei Wei,Michal Krawczyk,Wenqiu Wang,Huiyan Luo,Huiyan Luo,Ken Flagg,Shaohua Yi,William Shi,Qingli Quan,Kang Li,Lianghong Zheng,Heng Zhang,Bennett A. Caughey,Qi Zhao,Jiayi Hou,Runze Zhang,Yanxin Xu,Huimin Cai,Gen Li,Rui Hou,Zheng Zhong,Danni Lin,Xin Fu,Jie Zhu,Yaou Duan,Meixing Yu,Binwu Ying,Wengeng Zhang,Juan Wang,Edward Zhang,Charlotte Zhang,Oulan Li,Rongping Guo,Hannah Carter,Jian-Kang Zhu,Xiaoke Hao,Kang Zhang,Kang Zhang,Kang Zhang +40 more
TL;DR: This work identified an HCC-specific methylation marker panel by comparing HCC tissue and normal blood leukocytes and showed that methylation profiles of HCC tumour DNA and matched plasma ctDNA are highly correlated.
Journal ArticleDOI
Lanosterol reverses protein aggregation in cataracts
Ling Zhao,Xiang-Jun Chen,Jie Zhu,Yi-Bo Xi,Xu Yang,Li-Dan Hu,Hong Ouyang,Sherrina Patel,Xin Jin,Danni Lin,Frances Wu,Ken Flagg,Huimin Cai,Gen Li,Guiqun Cao,Ying Lin,Daniel Chen,Cindy Wen,Christopher Chung,Yandong Wang,Austin Qiu,Emily Yeh,Wenqiu Wang,Xun Hu,Seanna Grob,Ruben Abagyan,Zhiguang Su,Harry C. Tjondro,Xi-Juan Zhao,Hongrong Luo,Rui Hou,J. Jefferson,P. Perry,Weiwei Gao,Igor Kozak,David B. Granet,Yingrui Li,Xiaodong Sun,Jun Wang,Liangfang Zhang,Yizhi Liu,Yong-Bin Yan,Kang Zhang +42 more
TL;DR: In this paper, the authors identify two distinct homozygous LSS missense mutations (W581R and G588S) in two families with extensive congenital cataracts.
Journal ArticleDOI
DNA methylation markers for diagnosis and prognosis of common cancers.
Xiaoke Hao,Huiyan Luo,Michal Krawczyk,Wei Wei,Wei Wei,Wenqiu Wang,Juan Wang,Ken Flagg,Jiayi Hou,Heng Zhang,Shaohua Yi,Maryam Jafari,Danni Lin,Christopher Chung,Bennett A. Caughey,Gen Li,Debanjan Dhar,William Shi,Lianghong Zheng,Rui Hou,Jie Zhu,Liang Zhao,Xin Fu,Edward Zhang,Charlotte Zhang,Jian-Kang Zhu,Michael Karin,Rui-Hua Xu,Kang Zhang +28 more
TL;DR: The utility of DNA methylation profiles for differentiating tumors and normal tissues for four common cancers found that they could differentiate cancerous tissue from normal tissue with >95% accuracy and can predict prognosis and survival.
Journal ArticleDOI
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer
Huiyan Luo,Qi Zhao,Wei Wei,Lianghong Zheng,Shaohua Yi,Gen Li,Wenqiu Wang,Hui Sheng,Heng-Ying Pu,Hai-Yu Mo,Zhixiang Zuo,Zexian Liu,Li Chaofeng,Chuanbo Xie,Zhao-Lei Zeng,Weimin Li,Xiaoke Hao,Yuying Liu,Sumei Cao,Wanli Liu,Sarah Gibson,Kang Zhang,Kang Zhang,Guoliang Xu,Rui-Hua Xu +24 more
TL;DR: The authors identified and validated a methylation-based diagnostic score to help distinguish patients with colorectal cancer from healthy controls, as well as a prognostic score that correlated with patients’ survival, and found that a single ctDNA methylation marker could yield high sensitivity and specificity for identifying patients with cancer.
Journal ArticleDOI
Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial
Nicola G. Ghazi,Emad B. Abboud,Sawsan R. Nowilaty,Hisham Alkuraya,Abdulrahman Alhommadi,Huimin Cai,Rui Hou,Wen-Tao Deng,Sanford L. Boye,Abdulrahman Al-Maghamsi,Fahad Al Saikhan,Hassan Al-Dhibi,David G. Birch,Christopher Chung,Dilek Colak,Matthew M. LaVail,Douglas Vollrath,Kirsten E. Erger,Wenqiu Wang,Thomas J. Conlon,Kang Zhang,Kang Zhang,William W. Hauswirth,Fowzan S. Alkuraya +23 more
TL;DR: Gene therapy for MERTK-related RP using careful subretinal injection of rAAV2-VMD2-hMERTK is not associated with major side effects and may result in clinical improvement in a subset of patients, based on 2-year follow-up.